Eligibility Criteria

Sex: All
Age: Not specified
Healthy Volunteers: This study is NOT accepting healthy volunteers

Inclusion Criteria:

- **STEP 0 ELIGIBILITY CRITERIA:**
  - Patient must have a prior or current cancer diagnosis (e.g., solid tumor or hematologic malignancy) that fits into any one of the following categories:
  - Patient is receiving active treatment (defined as current treatment or treatment within the past 6 weeks) or will begin receiving treatment within the next 2 weeks for any central nervous system (CNS) or hematologic malignancy or metastatic (stage IV) solid tumor. Eligible treatment types for hematologic malignancy or metastatic cancer are chemotherapy, immunotherapy, monoclonal antibody therapy (e.g., rituximab, trastuzumab, cetuximab), targeted therapy (e.g., BRAF/MEK inhibitor, EGFR inhibitor), endocrine therapy, radiation therapy, or targeted radionuclide therapy; or
  - Patient has received an allogeneic stem cell transplant or chimeric antigen receptor (CAR)-T cell or other modified cellular therapy at any time; or
  - Patient is currently receiving treatment or prophylaxis for graft versus (vs.) host disease; or
  - Patient has received an autologous bone marrow transplant within the past 2 years.
  - Patient must have a pending or known positive viral test result for SARS-CoV-2.
  - Patients with prior negative viral SARS CoV-2 test(s) are eligible if they are being tested again.
  - Patients 18 years of age and older with prior positive viral SARS CoV-2 test(s) more than 14 days prior to enrollment to Step 1 are not eligible
  - Human immunodeficiency virus (HIV)-infected patients are eligible
  - Patients with CNS metastases are eligible
  - Co-enrollment on other clinical trials (for cancer or for COVID-19) is allowed

- **STEP 1 ELIGIBILITY CRITERIA:** Positive viral SARS CoV-2 test
  - Patient must have a documented positive viral SARS CoV-2 test
  - For patients 18 years of age or older, the specimen collection for the positive test must have occurred no earlier than 14 days prior to enrollment to Step 1
  - For patients under 18 years of age, the specimen collection for the positive test must have occurred after January 31, 2020
  - The viral test can be either a nucleic acid (PCR) test or an antigen test. Serological or antibody tests are not allowed. The test must have received Emergency Use Approval (EUA) from the Food and Drug Administration (FDA) and be performed in a Clinical Laboratory Improvement Act (CLIA) certified lab or patient care setting operating under a CLIA Certificate of Waiver. A full list of tests that have been approved under the EUA can be accessed at: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas Any specimen source (e.g., nasopharyngeal swab, oropharyngeal swab, etc.) is allowable for the viral SARS-CoV-2 test.

Conditions & Interventions

Interventions:
- Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
- Conditions:
  - COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Keywords: COVID-19

More Information

Contact(s): sfinder@umn.edu
Phase: Recruiting
IRB Number: NCT04387656
System ID: NCT04387656

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.